CIK: 0002077247
Total reported value
$436.5M
Reporting period: 2026-03-31 · Number of holdings: 27
Trails Edge Capital Partners, LP disclosed 27 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $436.5M and a quarterly turnover rate of 88.2%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "T"
Trails Edge Capital Partners, LP's disclosed holdings carry a Herfindahl concentration index of 0.054 — mathematically equivalent to about 19 equally-sized positions, close to its 27 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.65), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 10% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add MIRM
+946.1% $28.3M
Trim NRIX
0.0% -$6.0M
Add XENE
+7.2% $10.5M
Trim IMCR
0.0% -$3.1M
Trim CAMP
-2.2% -$3.6M
Trim VTVT
-39.6% -$3.7M
Showing top 26 holdings (of 27 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PCVX | Vaxcyte INC | Stock-Other | 8.82% | +0.41% | -10.17% | |
| 2 | XENE | Xenon Pharmaceuticals INC | Stock-Other | 8.53% | +1.92% | +7.19% | |
| 3 | DFTX | Definium Therapeutics INC | Stock-Other | 7.53% | +7.53% | NEW | |
| 4 | LBRX | Lb Pharmaceuticals INC | Stock-Other | 7.45% | -0.23% | -5.46% | |
| 5 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 7.05% | +6.43% | +946.11% | |
| 6 | NRIX | Nurix Therapeutics INC | Stock-Other | 6.19% | -1.98% | — | |
| 7 | RVMD | Revolution Medicines INC | Stock-Healthcare | 5.46% | +5.46% | NEW | |
| 8 | RCUS | Arcus Biosciences INC | Stock-Other | 5.19% | -0.21% | +14.36% | |
| 9 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 4.71% | -1.14% | — | |
| 10 | CYTK | Cytokinetics INC | Stock-Healthcare | 4.53% | +4.53% | NEW | |
| 11 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 3.76% | +3.76% | NEW | |
| 12 | NGNE | Neurogene INC | Stock-Other | 3.62% | -0.38% | -0.28% | |
| 13 | IVA | Inventiva SA - Adr | Stock-Other | 3.38% | +0.33% | — | |
| 14 | IKT | Inhibikase Therapeutics INC | Stock-Other | 3.10% | -0.03% | +30.42% | |
| 15 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 2.78% | +2.78% | NEW | |
| 16 | XFOR | X4 Pharmaceuticals INC | Stock-Other | 2.43% | -0.11% | — | |
| 17 | IMVT | Immunovant INC | Stock-Other | 2.36% | +0.85% | +72.40% | |
| 18 | DSGN | Design Therapeutics INC | Stock-Other | 2.08% | +2.08% | NEW | |
| 19 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 1.96% | -1.04% | -2.24% | |
| 20 | NERV | Minerva Neurosciences INC | Stock-Other | 1.96% | +1.96% | NEW | |
| 21 | PMN | Promis Neurosciences INC | Stock-Other | 1.62% | +1.62% | NEW | |
| 22 | ✓ | Stock-Other | 1.55% | +1.55% | NEW | ||
| 23 | IPSC | Century Therapeutics INC | Stock-Other | 1.27% | +1.27% | NEW | |
| 24 | VTVT | Vtv Therapeutics Inc- Cl A | Stock-Other | 1.27% | -1.01% | -39.58% | |
| 25 | FTH | Faeth Therapeutics INC | Stock-Other | 0.90% | +0.90% | NEW | |
| 26 | IRD | Opus Genetics INC | Stock-Other | 0.52% | +0.52% | NEW |
Performance for Q3 2026
+20.2%
Performance Last 4 Quarters
+23.5%
Based on 5 months of available history
Based on 86% of reported portfolio value with available pricing
Trails Edge Capital Partners, LP's most significant position changes for 2026-03-31: Sold out: Acadia Pharmaceuticals INC (ACAD); Sold out: Mind Medicine Mindmed INC (BRD1EUR); New buy: Definium Therapeutics INC (DFTX); New buy: Revolution Medicines INC (RVMD); New buy: Cytokinetics INC (CYTK).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MIRM | Mirum Pharmaceuticals INC | +6.4% | +946.11% | Add |
| 2 | XENE | Xenon Pharmaceuticals INC | +1.9% | +7.19% | Add |
| 3 | IMVT | Immunovant INC | +0.9% | +72.40% | Add |
| 4 | PCVX | Vaxcyte INC | +0.4% | -10.17% | Trim |
| 5 | IVA | Inventiva SA - Adr | +0.3% | — | Unchanged |
| 6 | IKT | Inhibikase Therapeutics INC | 0% | +30.42% | Add |
| 7 | XFOR | X4 Pharmaceuticals INC | -0.1% | — | Unchanged |
| 8 | RCUS | Arcus Biosciences INC | -0.2% | +14.36% | Add |
| 9 | LBRX | Lb Pharmaceuticals INC | -0.2% | -5.46% | Trim |
| 10 | NGNE | Neurogene INC | -0.4% | -0.28% | Trim |
| 11 | VTVT | Vtv Therapeutics Inc- Cl A | -1% | -39.58% | Trim |
| 12 | CAMP | Camp4 Therapeutics CORP | -1% | -2.24% | Trim |
| 13 | IMCR | Immunocore Holdings Plc-adr | -1.1% | — | Unchanged |
| 14 | NRIX | Nurix Therapeutics INC | -2% | — | Unchanged |
| 15 | ACAD | Acadia Pharmaceuticals INC | — | EXIT | Sold out |
| 16 | BRD1EUR | Mind Medicine Mindmed INC | — | EXIT | Sold out |
| 17 | DFTX | Definium Therapeutics INC | — | NEW | New buy |
| 18 | RVMD | Revolution Medicines INC | — | NEW | New buy |
| 19 | CYTK | Cytokinetics INC | — | NEW | New buy |
| 20 | TYRA | Tyra Biosciences INC | — | EXIT | Sold out |
| 21 | SNDX | Syndax Pharmaceuticals INC | — | NEW | New buy |
| 22 | AM6 | Amicus Therapeutics INC | — | EXIT | Sold out |
| 23 | APGE | Apogee Therapeutics INC | — | EXIT | Sold out |
| 24 | FDMT | 4d Molecular Therapeutics In | — | NEW | New buy |
| 25 | 430 | Terns Pharmaceuticals INC | — | EXIT | Sold out |
| 26 | MBX | Mbx Biosciences INC | — | EXIT | Sold out |
| 27 | DSGN | Design Therapeutics INC | — | NEW | New buy |
| 28 | NERV | Minerva Neurosciences INC | — | NEW | New buy |
| 29 | CMPX | Compass Therapeutics INC | — | EXIT | Sold out |
| 30 | PMN | Promis Neurosciences INC | — | NEW | New buy |
| 31 | ✓ | — | NEW | New buy | |
| 32 | IPSC | Century Therapeutics INC | — | NEW | New buy |
| 33 | FTH | Faeth Therapeutics INC | — | NEW | New buy |
| 34 | ELVN | Enliven Therapeutics INC | — | EXIT | Sold out |
| 35 | IRD | Opus Genetics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001861558
Total reported value
$436.5M
128 stks
2025-09-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0001910666
Total reported value
$436.4M
809 stks
2026-06-30
AUM within 0.0% of this institution
CIK 0001563690
Total reported value
$436.4M
192 stks
2026-06-30
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001727492
Total reported value
$1.5B
28 stks
2026-03-31
2 of the top 5 holdings overlap, including Vaxcyte INC
CIK 0000938206
Total reported value
$13.6B
356 stks
2026-03-31
1 of the top 5 holdings overlap, including Xenon Pharmaceuticals INC
CIK 0001158202
Total reported value
$1.3B
172 stks
2026-03-31
1 of the top 5 holdings overlap, including Mirum Pharmaceuticals INC